Kausar Suleman1,2, Ali Hassan Mushtaq3, Emaan Haque3, Ahmed Ali Badran1,4, Dahish Ajarim1, Ahmed Mohammed Elashwah1,5, Ahmed Mostafa Gad1,4, Amgad Shaheen Abdelsamad1,6, Ayman Omar1,2,7, Khurshid Ahmed Khan1, Taher Al-Tweigeri1, Ayman Elshentenawy1,5, Adher Alsayed1. 1. Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. 2. Associate Professor for Al Faisal University, Riyadh, Saudi Arabia. 3. Al Faisal University, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia. 4. Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 5. Kasr Aleini center of Clinical Oncology and Nuclear Medicine (NEMROCK), Cairo University, Cairo, Egypt. 6. Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt. 7. Department of Clinical Oncology and Nuclear Medicine, Suez Canal University Hospital, Ismailia, Egypt.
Abstract
INTRODUCTION: Human epidermal growth factor receptor 2 (HER-2) targeted therapy regimens can improve tumor response in HER-2-positive metastatic breast cancer (MBC), with overall survival benefits. OBJECTIVE: We evaluated the efficacy of dual HER-2 blockade combined with chemotherapy for HER-2-positive MBC patients as a first-line therapy in our patient population. PATIENTS AND METHODS: We identified 75 patients at King Faisal Specialist Hospital and Research Center that received trastuzumab, pertuzumab, and docetaxel as a first-line therapy in HER-2 positive MBC in 2013-2016. RESULTS: Median age at diagnosis was 45 years; 54.7% were estrogen receptor (ER)-positive. 10% of patients presented with only bone metastasis. The median follow-up time was 36 months with an objective response rate of 74.7% (complete response [CR] 18.7%; partial response [PR] 56%). The 5-year progression-free survival (PFS) and overall survival (OS) were 21% and 71.9% respectively, with a median PFS of 36 months (95% confidence interval [CI] 23.6-48.4). The 5-year OS for ER-negative and ER-positive patients was 93.9% and 59.4% respectively (p = 0.189); 23 patients experienced grade 1/2 toxicity and 2 patients had grade 3/4 toxicity. In terms of OS and PFS, the site of metastasis did not make any significant difference. CONCLUSIONS: First line pertuzumab, trastuzumab, and docetaxel for HER-2-positive MBC patients was found to be an effective and safe therapy in the Saudi population. This finding was consistent with the results seen in the CLEOPATRA trials.
INTRODUCTION: Human epidermal growth factor receptor 2 (HER-2) targeted therapy regimens can improve tumor response in HER-2-positive metastatic breast cancer (MBC), with overall survival benefits. OBJECTIVE: We evaluated the efficacy of dual HER-2 blockade combined with chemotherapy for HER-2-positive MBC patients as a first-line therapy in our patient population. PATIENTS AND METHODS: We identified 75 patients at King Faisal Specialist Hospital and Research Center that received trastuzumab, pertuzumab, and docetaxel as a first-line therapy in HER-2 positive MBC in 2013-2016. RESULTS: Median age at diagnosis was 45 years; 54.7% were estrogen receptor (ER)-positive. 10% of patients presented with only bone metastasis. The median follow-up time was 36 months with an objective response rate of 74.7% (complete response [CR] 18.7%; partial response [PR] 56%). The 5-year progression-free survival (PFS) and overall survival (OS) were 21% and 71.9% respectively, with a median PFS of 36 months (95% confidence interval [CI] 23.6-48.4). The 5-year OS for ER-negative and ER-positive patients was 93.9% and 59.4% respectively (p = 0.189); 23 patients experienced grade 1/2 toxicity and 2 patients had grade 3/4 toxicity. In terms of OS and PFS, the site of metastasis did not make any significant difference. CONCLUSIONS: First line pertuzumab, trastuzumab, and docetaxel for HER-2-positive MBC patients was found to be an effective and safe therapy in the Saudi population. This finding was consistent with the results seen in the CLEOPATRA trials.
Authors: Mizuki Nishino; Jyothi P Jagannathan; Nikhil H Ramaiya; Annick D Van den Abbeele Journal: AJR Am J Roentgenol Date: 2010-08 Impact factor: 3.959
Authors: Rashmi K Murthy; Ankur Varma; Priyankana Mishra; Kenneth R Hess; Elliana Young; James L Murray; Kimberly H Koenig; Stacy L Moulder; Amal Melhem-Bertrandt; Sharon H Giordano; Daniel Booser; Vicente Valero; Gabriel N Hortobagyi; Francisco J Esteva Journal: Cancer Date: 2014-03-26 Impact factor: 6.860
Authors: T Bachelot; E Ciruelos; A Schneeweiss; F Puglisi; T Peretz-Yablonski; I Bondarenko; S Paluch-Shimon; A Wardley; J-L Merot; Y du Toit; V Easton; N Lindegger; D Miles Journal: Ann Oncol Date: 2019-05-01 Impact factor: 32.976
Authors: Sandra M Swain; José Baselga; Sung-Bae Kim; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Sarah Heeson; Emma Clark; Graham Ross; Mark C Benyunes; Javier Cortés Journal: N Engl J Med Date: 2015-02-19 Impact factor: 91.245
Authors: Michel Marty; Francesco Cognetti; Dominique Maraninchi; Ray Snyder; Louis Mauriac; Michèle Tubiana-Hulin; Stephen Chan; David Grimes; Antonio Antón; Ana Lluch; John Kennedy; Kenneth O'Byrne; PierFranco Conte; Michael Green; Carol Ward; Karen Mayne; Jean-Marc Extra Journal: J Clin Oncol Date: 2005-05-23 Impact factor: 44.544
Authors: Sandra M Swain; Sung-Bae Kim; Javier Cortés; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Adam Knott; Emma Clark; Graham Ross; Mark C Benyunes; José Baselga Journal: Lancet Oncol Date: 2013-04-18 Impact factor: 41.316
Authors: Hussein A Assi; Katia E Khoury; Haifa Dbouk; Lana E Khalil; Tarek H Mouhieddine; Nagi S El Saghir Journal: J Thorac Dis Date: 2013-06 Impact factor: 2.895